These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37640233)

  • 21. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
    He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
    MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chasing SARS-CoV-2 XBB.1.16 Recombinant Lineage in India and the Clinical Profile of XBB.1.16 Cases in Maharashtra, India.
    Karyakarte RP; Das R; Rajmane MV; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Kulkarni PP; Nizarudeen S; Joshi S; Karmodiya K; Potdar V
    Cureus; 2023 Jun; 15(6):e39816. PubMed ID: 37397651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular In-Depth on the Epidemiological Expansion of SARS-CoV-2 XBB.1.5.
    Scarpa F; Azzena I; Locci C; Casu M; Fiori PL; Ciccozzi A; Angeletti S; Imperia E; Giovanetti M; Maruotti A; Borsetti A; Cauda R; Cassone A; Via A; Pascarella S; Sanna D; Ciccozzi M
    Microorganisms; 2023 Mar; 11(4):. PubMed ID: 37110335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant.
    Islam MA; Kaifa FH; Chandran D; Bhattacharya M; Chakraborty C; Bhattacharya P; Dhama K
    Front Microbiol; 2023; 14():1154296. PubMed ID: 37143546
    [No Abstract]   [Full Text] [Related]  

  • 25. Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5.
    Entzminger KC; Fleming JK; Entzminger PD; Espinosa LY; Samadi A; Hiramoto Y; Okumura SCJ; Maruyama T
    Antib Ther; 2023 Apr; 6(2):108-118. PubMed ID: 37324547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant.
    Scarpa F; Azzena I; Ciccozzi A; Giovanetti M; Locci C; Casu M; Fiori PL; Borsetti A; Cella E; Quaranta M; Pascarella S; Sanna D; Ciccozzi M
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness.
    John OO; Olabode ON; Lucero-Prisno Iii DE; Adebimpe OT; Singh A
    J Taibah Univ Med Sci; 2023 Dec; 18(6):1285-1287. PubMed ID: 37250814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severity outcomes associated with SARS-CoV-2 XBB variants, an observational analysis.
    Klein EY; Fall A; Norton JM; Eldesouki RE; Abdullah O; Han L; Yunker M; Mostafa HH
    J Clin Virol; 2023 Aug; 165():105500. PubMed ID: 37290254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The assessment of Twitter discourse on the new COVID-19 variant, XBB.1.5, through social network analysis.
    Yuda Kusuma I; Pratiwi H; Fitri Khairunnisa S; Ayu Eka Pitaloka D; Arizandi Kurnianto A
    Vaccine X; 2023 Aug; 14():100322. PubMed ID: 37317688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural evolution of SARS-CoV-2 omicron in human receptor recognition.
    Zhang W; Shi K; Geng Q; Herbst M; Wang M; Huang L; Bu F; Liu B; Aihara H; Li F
    J Virol; 2023 Aug; 97(8):e0082223. PubMed ID: 37578233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.
    Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY
    Front Public Health; 2023; 11():1146059. PubMed ID: 37081954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.
    Fabiani M; Mateo-Urdiales A; Sacco C; Rota MC; Fotakis EA; Petrone D; Del Manso M; Siddu A; Stefanelli P; Bella A; Riccardo F; Rezza G; Palamara AT; Brusaferro S; Pezzotti P;
    Euro Surveill; 2023 Aug; 28(32):. PubMed ID: 37561053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants.
    Özüdoğru O; Bahçe YG; Acer Ö
    Ir J Med Sci; 2023 Apr; 192(2):751-756. PubMed ID: 35711013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Automated antigen assays display a high heterogeneity for the detection of SARS-CoV-2 variants of concern, including several Omicron sublineages.
    Osterman A; Krenn F; Iglhaut M; Badell I; Lehner A; Späth PM; Stern M; Both H; Bender S; Muenchhoff M; Graf A; Krebs S; Blum H; Grimmer T; Durner J; Czibere L; Dächert C; Grzimek-Koschewa N; Protzer U; Kaderali L; Baldauf HM; Keppler OT
    Med Microbiol Immunol; 2023 Oct; 212(5):307-322. PubMed ID: 37561226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
    Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
    Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
    Tamura T; Ito J; Uriu K; Zahradnik J; Kida I; Anraku Y; Nasser H; Shofa M; Oda Y; Lytras S; Nao N; Itakura Y; Deguchi S; Suzuki R; Wang L; Begum MM; Kita S; Yajima H; Sasaki J; Sasaki-Tabata K; Shimizu R; Tsuda M; Kosugi Y; Fujita S; Pan L; Sauter D; Yoshimatsu K; Suzuki S; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Yamamoto Y; Nagamoto T; Schreiber G; Maenaka K; ; Hashiguchi T; Ikeda T; Fukuhara T; Saito A; Tanaka S; Matsuno K; Takayama K; Sato K
    Nat Commun; 2023 May; 14(1):2800. PubMed ID: 37193706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV CH.1.1 Variant: Genomic and Structural Insight.
    Bazzani L; Imperia E; Scarpa F; Sanna D; Casu M; Borsetti A; Pascarella S; Petrosillo N; Cella E; Giovanetti M; Ciccozzi M
    Infect Dis Rep; 2023 May; 15(3):292-298. PubMed ID: 37367188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore.
    Pung R; Kong XP; Cui L; Chae SR; Chen MI; Lee VJ; Ho ZJM
    Lancet Reg Health West Pac; 2023 Aug; 37():100849. PubMed ID: 37554470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
    León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.